Taenaka N, Terada N, Takahashi H, Tachimori Y, Okada T, Takezawa J, Shimada Y, Yoshiya I
Crit Care Med. 1986 May;14(5):481-3. doi: 10.1097/00003246-198605000-00010.
The efficacy of gabexate mesilate (FOY), a synthetic serine proteinase inhibitor, was compared with that of heparin in preventing the acceleration of bleeding after hemodialysis. Transfused blood volume (TBV) was measured 24 h before and after 24 dialyses in 14 bleeding patients with impaired hemostatic function. The predialysis TBV did not differ significantly between heparin and FOY groups; however, TBV was significantly (p less than .05) larger after heparin dialysis than after FOY dialysis. After dialysis, TBV was increased in eight of nine heparin patients, compared to only three of 15 FOY subjects (p less than .01). FOY is an effective agent and may decrease postdialysis bleeding complications in certain high-risk patients.
将合成丝氨酸蛋白酶抑制剂甲磺酸加贝酯（FOY）与肝素在预防血液透析后出血加速方面的疗效进行了比较。对14名止血功能受损的出血患者在24次透析前后24小时测量了输血量（TBV）。肝素组和FOY组透析前的TBV无显著差异；然而，肝素透析后的TBV显著（p<0.05）大于FOY透析后。透析后，9名肝素治疗患者中有8名TBV增加，而15名FOY治疗患者中只有3名（p<0.01）。FOY是一种有效药物，可能会减少某些高危患者透析后的出血并发症。
